Vertex Pharma stock: BofA cuts target to USD 667 for Vertex Pharma stock
Published on 10/20/2026 at 15:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTarget and reporting date
- On October 12, 2026, BofA Securities cut its Vertex target from USD 672.00 to USD 667.00.
- Vertex Pharmaceuticals will report third-quarter 2026 results on November 2, 2026.
- Vertex Pharma stock costs EUR 449.30 at Lang & Schwarz on October 20, 2026 at 3:18 p.m. CEST, 0.17 percent below the Tradegate close of October 19, 2026.
Vertex Pharma (ISIN US92532F1003) faces a USD 667.00 price target from BofA Securities after the firm cut it from USD 672.00 on October 12, 2026, according to Investing.com. At USD 508.93 on Nasdaq on October 20, 2026 at 9:30 a.m. ET, that target stood 31.05 percent above the US share price. Vertex Pharma was trading at EUR 449.30 at Lang & Schwarz on October 20, 2026 at 3:18 p.m. CEST, down 0.17 percent versus the Tradegate close of October 19, 2026.
Revenue growth sets the backdrop
Vertex reported USD 3.33 billion in revenue for the second quarter of 2026, up 12.50 percent from USD 2.96 billion a year earlier. Net income reached USD 1.10 billion, an increase of 6.50 percent, while diluted earnings per share rose to USD 4.31 from USD 3.99. These figures were reported in the quarter ended June 30, 2026, as detailed by TickerScout.
Stock stays inside its yearly range
On October 20, 2026, the Nasdaq share price of USD 508.93 sat between the 52-week low of USD 403.16 and the 52-week high of USD 560.25. Vertex had a market capitalization of USD 129.0 billion and a price-to-earnings ratio of 29.22 on the same date. The euro quotation therefore remains a separate German trading reference for investors comparing venues.
Valuation and November 2 results
Vertex will report third-quarter 2026 results on November 2, 2026, after the US market close, with its conference call scheduled for 4:30 p.m. ET, according to the company's release dated October 7, 2026, published through Vertex Pharmaceuticals. The date gives the next clear catalyst for the valuation, while the BofA target remains above the Nasdaq price.
Comparison with peers
Vertex Pharma: down 0.17 percent, price-to-earnings ratio 29.22, market capitalization USD 129.0 billion.
Regeneron Pharmaceuticals (Nasdaq, USD): up 1.61 percent, price-to-earnings ratio 19.34, market capitalization USD 81.8 billion.
Gilead Sciences (Nasdaq, USD): up 1.45 percent, negative price-to-earnings ratio of 57.33, market capitalization USD 192.5 billion.
Euro quote remains nearly unchanged
The German quotation was EUR 0.75 below the Tradegate close of October 19, 2026, leaving the daily move at minus 0.17 percent for investors using the euro perspective.
The further course of trading is shown by the continuously updated real-time quote of Vertex Pharma stock.
Vertex Pharma at a glance
- Company: Vertex Pharmaceuticals Incorporated
- ISIN: US92532F1003
- Ticker: VRTX
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 20, 2026, 3:18 p.m. CEST): EUR 449.30
- Change versus Tradegate close: minus 0.17 percent
- Tradegate close (October 19, 2026): EUR 450.05
- Market capitalization: USD 129.0 billion (as of October 20, 2026)
- 52-week range: USD 403.16-560.25 (as of October 20, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 2, 2026
Market context: Market report S&P 500.
